Antitumor activity and immune-related gene expression changes following recombinant Mycobacterium smegmatis treatment in a mouse model of bladder cancer
Year: 2026
Type: article
Abstract: Bladder cancer requires additional therapeutic strategies because of frequent recurrence and progression risk. We evaluated recombinant Mycobacterium smegmatis expressing a human macrophage migration inhibitory factor–interleukin-7 fusion protein (rSmeg-hMIF-hIL-7) in a syngeneic subcutaneous MBT-2 bladder cancer model. Among mice that developed measurable tumors, intraperitoneally treated mice showed reduced tumor growth and longer endpoint-free survival, defined as time to death or humane-endpoint euthanasia. RNA sequencing of four control and three treated tumors identified 116 differentially expressed genes at a fold-change magnitude ≥ 2 and false discovery rate (FDR) < 0.05. Enrichment analyses highlighted immune-related transcriptional differences, although tissue-collection timing and tumor burden limited their attribution to treatment. Cross-species expression comparison identified five exploratory candidates: CCL15, CCRL2, ST3GAL5, SIGLEC6, and TMEM255A. Four showed FDR-significant survival associations in exploratory unadjusted Cox analyses within the same TCGA-BLCA cohort. Expression patterns concordant with those in treated mouse tumors were also associated with papillary histology. RT-qPCR using the same biological samples supported increased Ccl6 and St3gal5 expression after multiple-testing correction. These findings support the antitumor potential of rSmeg-hMIF-hIL-7 and provide exploratory links between murine tumor transcriptional differences and human bladder cancer characteristics.
Source: Scientific Reports
Authors: Dongwook Song(Data curation, Formal analysis, Validation, Visualization, Writing – original draft), Jae Won Park(Conceptualization), Gisub Choi(Investigation, Resources), Baek Gil Kim(Visualization, Writing – review & editing), Hyunho Han(Conceptualization, Methodology, Project administration, Supervision, Writing – review & editing), Young Deuk Choi(Conceptualization, Funding acquisition, Supervision, Writing – review & editing)
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7204528785
